Physician profile
Nick Mamalis
NPI 1750496220
$9,962.15
in general payments reported to CMS, 2019-2025
7 companies · $7,277 in 2025
The $7,277 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $938 · 2022: $154 · 2025: $7,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,225 · Food and Beverage: $52.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,225.00 |
| Food and Beverage | $52.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $7,225.00 | 2025 | Envista Mx60 Iol, Crystalens Accommodating Iol (At-52ao), Envista Envy Iol |
| Johnson & Johnson Surgical Vision, INC. | $1,500.00 | 2019 | |
| Allergan, INC. | $937.50 | 2020 | |
| Alcon Research LLC | $154.30 | 2022 | |
| Alcon Vision LLC | $78.22 | 2019-2025 | Unity |
| Carl Zeiss Meditec, INC. | $67.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Mamalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.